TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Expression of protein A in circulating exosomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eye gaze measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endothelial function (forearm dilation, FMD - %)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Autophagy induction activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response to Dry Mouth Discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants with a live birth
Endpoint domain: Mortality/survival
Primary endpoint: Total and free plasma concentration of antibiotics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Free tissue concentration of antibiotics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Probability of target attainment of PK/PD index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate (Cohorts 1 and 2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Event-free survival (Cohort 3)
Endpoint domain: Mortality/survival
Primary endpoint: Extra vascular lung water (EVLW)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve (AUC0-last) of MK-6183
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum Plasma Drug Concentration (Cmax) of MK-6183
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Apparent Plasma Half-life (t½) of MK-6183
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 2-year graft-vs.-host disease- and relapse-free survival
Endpoint domain: Mortality/survival
Primary endpoint: HABIT scores for patients
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: HABIT scores for physicians
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in cholinesterase level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Confirmed COVID-19 diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Primary outcome measurement not specified
Endpoint domain: null
Endpoint subdomain: null
Primary endpoint: Change in sleep symptoms
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Tubular Residual Kidney Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in symptoms - Patient Health Questionnaire - 9 Item
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in symptoms (Quick Inventory of Depressive Symptomatology)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in quality of life (Quality of Life Enjoyment and Satisfaction Questionnaire)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Echocardiography parameters (LVEF, LVESV, LVEDV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of long-term persistence of TCRγδ+ cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Hurst coefficient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of ONO-9054
Endpoint domain: Adverse events/effects
Primary endpoint: parasitological clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Glycated haemoglobin (A1C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With TEAE and SAE
Endpoint domain: Adverse events/effects
Primary endpoint: Incretins plasmatic levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Accurate Confirmation of Completed Abortion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative implantation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Changes in M-protein Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of Ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Clinical improvement using the Fibromyalgia Impact Questionnaire (FIQ)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Clinical improvement using the Symptom Severity Score (SSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical improvement using the Widespread Pain Index (WPI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Long-term safety and tolerability of mitapivat
Endpoint domain: Adverse events/effects
Primary endpoint: Total Dose of Opioid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to peak plasma concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VCO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: diagnostic sensitivity of RFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Completed the Study at 4 Weeks Without Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Obstructive Sleep Apnea (OSA) Severity as a Result of Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall response rate (ORR) - cohort 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Objective response rate (ORR) - cohort 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of patients with intervention compliance
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Safety of RH genotype matched D+ RBCs
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of schizophrenia
Endpoint domain: Mortality/survival
Primary endpoint: Mean Post-treatment Tumor Progesterone Receptor H-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Weight loss expressed as Body Mass Index and Percentage of excess weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IL-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Renal impairment/renal function deterioration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of infusion related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: 400 meter walk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Pathological complete responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of astigmatism as determined by refraction assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of corneal aberrations as determined by corneal topography assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Inflammation on Renal Allograft Biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Successful Engraftment of Probiotic
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Investigator Global Assessment (IGA) Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Safety Profile and Tolerability Using Acne Lesion Counts
Endpoint domain: Adverse events/effects
Primary endpoint: Peak of the S' wave
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Strain in the right ventricle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Glycemia after childbirth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Patient Empowerment Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Safety of unselected autologous HSCT
Endpoint domain: Adverse events/effects
Primary endpoint: Participant Compliance
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Expression of biomarkers of kidney injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Changes in cytokine levels in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pain modulation at amputation sites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amputation Mobility Predictor with prosthesis (AMPPRO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minutes walking and standing per day
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Fistula repair breakdown
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Atorvastatin AUCt
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Atorvastatin Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fenofibric acid AUCt
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fenofibric acid Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: serum BDNF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retinal morphology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: area under the serum insulin concentration time curve from time 0 to 8H (INS-AUC0-8H)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: area under the glucose infusion rate curve (GIR) necessary to maintain euglycemia during the euglycemic clamp over 8 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Dose of SCY-078 That Achieves the Target Exposure (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment success according to Physician's Global Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in receipt of CRC screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of ECG abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Motricity Index - arm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Sinus Symptom Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degrees of pain experienced by the children
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Degrees of fear experienced by the children
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Liver Graft Survival
Endpoint domain: Mortality/survival
Primary endpoint: pneumothorax recurrence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score on Follow-up Self-Management Ability Scale (SMAS-30)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Back Pain Attitude Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Low Back Pain Knowledge questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Visual analogue scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Medication Continuation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Referrals to Correctional Health Services (CHS)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Referrals to Coordinated Specialty Care (CSC)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Successful withdrawal from anticholinergic antiparkinsonian agents
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: insulin mediated inhibition of adipose tissue lipid mobilization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of adverse events after each vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Reinforcing Drug Effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from a composite of serious adverse events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Freedom from documented symptomatic atrial fibrillation (AF), atrial flutter (AFL) and atrial tachycardia (AT) episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Muscle Fiber Composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in symptoms and quality of life
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: First Occurrence of Composite Endpoint (Death, Nonfatal MI, Class IV HF)
Endpoint domain: Mortality/survival
Primary endpoint: Recurrent rate of ischemic stroke/transient ischemic stroke
Endpoint domain: Mortality/survival
Primary endpoint: Area Under the Concentration Versus Time Curve (AUC[0-tlast])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response on Clinical Global Impression-Improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Hemoglobin A1C changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: optic nerve head pressure-flow relationship
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Composite Pharmacokinetic (PK) profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with hemodynamically significant coronary heart disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Visual Acuity Letter Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Survived to Hospital Discharge
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of subjects achieving post-vaccination Hemagglutination Inhibition (HI) antibody titer ≥ 1:40
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of subjects achieving post-vaccination seroconversion for Hemagglutination Inhibition (HI) antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: The percentage of subjects reporting solicited adverse events from the date of vaccination until 7 days after each vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Oral mucositis grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain intensity: Visual analog scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Peak Detrusor Pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Maslach Burnout Inventory (MBI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Dose Changes Required
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: QTc interval Prolongation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Concordance of capillary and venous sampling for natremia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Concordance of capillary and venous sampling for kalemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Concordance of capillary and venous sampling for chloremia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants With Grade 2 or Higher Autoimmune Events
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of dysfunction motivating catheter removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration of metabolic effect on blood glucose control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Sustained Abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Diaphragmatic electromyographic activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Diagnostic accuracy of multiparametric MR imaging (mpMRI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PT specific antibody GMC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serious adverse events (SAEs), adverse events (AEs) leading to withdrawal, adverse event of special interest (AESI) (including vaccine-enhanced disease) and deaths
Endpoint domain: Adverse events/effects
Primary endpoint: Laboratory-confirmed (virologic method) symptomatic SARS-CoV-2 infection
Endpoint domain: Adverse events/effects
Primary endpoint: Size of parapapillary atrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: AUC0-24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Percentage of Participants who Achieve an Investigator's Global Assessment (IGA) Score of Cleared (0) or Minimal (1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants who Achieve Psoriasis Area and Severity Index (PASI) 75 Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bone height gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Monthly Headache Days During Entire Study Period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Local Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: EuroQol (EQ-5D-5L)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Two-year Progression-free Survival (PFS)
Endpoint domain: Mortality/survival
Primary endpoint: PEG Tube Dependence
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Participants' self-reported overall acceptability of PrEP
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: The level of community interest in PrEP
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Composite support score
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: 6 month progression-free-survival-rate (PFS6)
Endpoint domain: Mortality/survival
Primary endpoint: Change in Cognitive/Memory Ability
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Percent Reduction in Oral Corticosteroid Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Homework quantity and quality
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Homework adherence
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Homework competence
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Diagnosis of lymph node metastasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Minutes of Physical Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in percentage of patients' adherence to HBPM recommendations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fluoroscopy time during ablation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Total ablation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence and severity of Participants with TaperGuard ETT
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence and severity of Participants with Cylindrical ETT
Endpoint domain: Adverse events/effects
Primary endpoint: Dysphagia symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Average Daily Subject Reported Total Nasal Symptom Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NIRS measurement after block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: presence of White Adipose Tissue Inflammation (WATi)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of On-treatment Pregnancies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Tolerance of resuscitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in HbA1c value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Oxford hip score (OHS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Frequency of local and systemic reactogenicity signs and symptoms
Endpoint domain: Adverse events/effects